ArticleEndocrine2026
IGF2BP3 mediates the mRNA upregulation of NLRP3 to promote parathyroid cell proliferation in chronic kidney disease via an m⁶A-dependent manner.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo investigate the underlying mechanism of NLRP3 in the pathogenesis of parathyroid hyperplasia.
methodsParathyroid glands (PGs) (n = 35) were obtained from 10 maintenance hemodialysis patients undergoing parathyroidectomy. A secondary hyperparathyroidism (SHPT) model was induced in rats by 5/6 nephrectomy followed by a high‑phosphate diet. Serum levels of calcium, phosphorus, creatinine, blood urea nitrogen (BUN), and intact parathyroid hormone (PTH) were measured. The expression of IGF2BP3 and NLRP3 was evaluated using quantitative reverse‑transcription polymerase chain reaction and Western blotting. NLRP3 mRNA stability was examined through RNA decay assays, and its translation was assessed by polysome profiling. RNA immunoprecipitation was performed to confirm the binding of IGF2BP3 to NLRP3 mRNA, while N⁶‑methyladenosine (m⁶A) modification levels in NLRP3 mRNA were measured via m⁶A‑RIP.
resultsNLRP3 expression was detected in pathological parathyroid tissues from chronic kidney disease patients with SHPT. Compared with less severe diffuse hyperplastic nodules, NLRP3 expression was significantly higher in nodular hyperplastic PG tissues. In SHPT rats, both IGF2BP3 and NLRP3 were upregulated in PG tissues. Knockdown of IGF2BP3 or NLRP3 reduced serum PTH levels and suppressed PG hyperplasia in SHPT rats. IGF2BP3 regulated NLRP3 expression in PGs through m⁶A‑dependent mechanisms by modulating NLRP3 mRNA stability and translation. NLRP3 overexpression reversed the phenotypic effects of IGF2BP3 knockdown in PG tissues of SHPT rats.
conclusionIGF2BP3 enhances NLRP3 mRNA stability and translation via m⁶A modification, thereby aggravating SHPT and parathyroid hyperplasia.
Indexed as
Identifiers
42429919What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.